Pharmaceuticals occupiers in São Paulo typically cluster in Vila Olímpia & Berrini, plan ~220 sqft per seat at high-end fit-out ($1900–2800/sqft), and pay around 250 BRL/sqft ($56 USD) on Class A.
Pharmaceuticals occupiers in São Paulo typically cluster in Vila Olímpia & Berrini, plan ~220 sqft per seat at high-end fit-out">fit-out ($1900–2800/sqft), and pay around 250 BRL/sqft ($56 USD) on Class A.
Pharmaceuticals occupiers in São Paulo typically anchor in Vila Olímpia & Berrini. Tech, consulting, banking, retail HQs, telecom.
Class A rent in São Paulo runs 250 BRL/sqft ($56 USD) on a 5-year lease with 6 months free. Prime submarkets sit at or modestly above the city index.
Typical pharmaceuticals fit-out targets high-end specification at $1900–2800/sqft. Branded reception, full client-facing programming, premium furniture, and specialist AV are standard.
Plan around 220 sqft per seat blended (workstation + circulation + amenity). A 100-headcount pharma office in São Paulo typically targets 22,000 sqft of leasable area.
Commercial and medical-affairs teams cluster near academic-medical anchors; large floor plates support cross-functional brand teams. Deep banking, professional services, and tech talent. Strong feed from USP, FGV, Insper, and ITA. Portuguese-English bilingual professional base in international corporate.
Headline corporate tax: 34%. Net leases. 5-year terms standard with statutory renewal rights under Brazilian commercial lease law (Lei do Inquilinato). Free rent of 4-9 months and TI of BRL 600-1,200/sqm typical.
| city | São Paulo |
|---|---|
| industry | Pharmaceuticals |
| naics | 3254, 5417 |
| preferredSubmarket | Vila Olímpia & Berrini |
| preferredFitoutSpec | High-end |
| fitoutBand | $1900–2800/sqft |
| sqftPerSeat | 220 |
| classARentLocal | 250 BRL/sqft/yr |
| classARentUsd | $56/sqft/yr |
| vacancyPct | 19.4% |
| typicalLeaseYears | 5 |
| typicalRentFreeMonths | 6 |
| talentIndex | 80 |
| corporateTaxPct | 34% |
Reviewed by Miriam Hollander — Lead market analyst. Last updated 2026-04-15. See our methodology and editorial standards.